Eagle Pharmaceuticals Reaches Agreement to Acquire Acacia Pharma

New Jersey-based Eagle Pharmaceuticals, Inc. has reached agreement on the terms to acquire Acacia Pharma Group plc. The terms of the proposed transaction value Acacia Pharma’s existing issued and to be issued share capital at approximately €94,700,000. The terms of the proposed transaction also provide for Eagle to guarantee approximately €25.0 million of debt within the Acacia Pharma group. 

The proposed transaction has been approved by the boards of directors of both companies and is expected to close in late 2Q22, subject to customary closing conditions. 

Eagle will gain two currently marketed, acute care, hospital products. BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting (PONV) despite prophylaxis. BARHEMSYS is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV. The total estimated annual U.S. addressable market for prophylaxis and rescue is $2.7 billion. 

Eagle will also gain BYFAVO, indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less, with an estimated total addressable market in procedural sedation of more than $0.4 billion per year in the U.S.

“We are delighted to announce that we have agreed to terms for the proposed acquisition of Acacia Pharma. This will be a very important acquisition for us, both financially and strategically. In recent years, the pharmaceutical industry has witnessed slower uptake of new products and longer ramp periods. In the face of further challenges brought about by the COVID-19 pandemic, many smaller underfunded companies experienced significant hurdles launching products. We therefore believe that Eagle is well suited to drive uptake of these two new products, building from Acacia Pharma’s established foundation since its launch, through our experienced and specialized hospital-based sales organization with minimal additional infrastructure,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.